An overview of gene therapy in head and neck cancer

Indian Journal of Human Genetics

Volumn 19, Issue 3, 2013, Pages 282-290

  Bali, Amit ^a   Bali, Deepika ^b   Sharma, Ashutosh ^a  

^a M M COLLEGE OF DENTAL SCIENCES AND RESEARCH   (India)

^b DAV (C) Dental College and Hospital   (India)

Author keywords

Gene addition therapy; gene therapy; head and neck cancer; immunotherapy; suicide gene

Indexed keywords

CANCER VACCINE; COMPLEMENTARY RNA; E1B PROTEIN; G 207; GANCICLOVIR; LONTUCIREV; NV 1020; OAS 403; ONCOLYTIC ADENOVIRUS; PROTEIN P27; PROTEIN P53; SMALL INTERFERING RNA; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ADENOVIRUS; APOPTOSIS; CANCER CELL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CELL CYCLE PROGRESSION; CELL KILLING; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOTOXICITY; DNA SYNTHESIS; GENE MUTATION; GLIOMA; HEAD AND NECK CANCER; HERPES VIRUS; HUMAN; MOUTH CANCER; ONCOLYTIC VIROTHERAPY; RETROVIRUS; REVIEW; SQUAMOUS CELL CARCINOMA; SUICIDE GENE THERAPY; THERAPY EFFECT; TONGUE CANCER; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

EID: 84887582823     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.120811     Document Type: Review

References (55)

1. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 2003;82:11-6
2. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003;9:5055-67
3. Ayllón Barbellido S, Campo Trapero J, Cano Sánchez J, Perea García MA, Escudero Castaño N, Bascones Martínez A. Gene therapy in the management of oral cancer: Review of the literature. Med Oral Patol Oral Cir Bucal 2008;13:E15-21
4. Cross D, Burmester JK. Gene therapy for cancer treatment: Past, present and future. Clin Med Res 2006;4:218-27
5. Cardinali M, Jakus J, Shah S, Ensley JF, Robbins KC, Yeudall WA. p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. Oral Oncol 1998;34:211-8
6. Clayman GL. The current status of gene therapy. Semin Oncol 2000;27 Suppl 8:39-43
7. Clayman GL, Trapnell BC, Mittereder N, Liu TJ, Eicher S, Zhang S, et al. Transduction of normal and malignant oral epithelium by an adenovirus vector: The effect of dose and treatment time on transduction efficiency and tissue penetration. Cancer Gene Ther 1995;2:105-11
8. Supriatno, Harada K, Kawaguchi S, Onoue T, Yoshida H, Sato M. Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line. Oral Oncol 2004;40:679-87
9. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al. Phase I-II trial of ONYX-015in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005;12:437-45
10. Liu X, Huang H, Wang J, Wang C, Wang M, Zhang B, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011;82:17-23
11. Shi H, Wang J, Dong F, Wang X, Li H, Hou Y. The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma. BMC Cancer 2009;9:456
12. Yang Y, Ge PJ, Jiang L, Li FL, Zhu QY. Modulation of growth and angiogenic potential of oral squamous carcinoma cells in vitro using salvianolic acid B. BMC Complement Altern Med 2011;11:54
13. Uchida D, Onoue T, Begum NM, Kuribayashi N, Tomizuka Y, Tamatani T, et al. Vesnarinone downregulates CXCR4 expression via upregulation of Krüppel-like factor 2 in oral cancer cells. Mol Cancer 2009;8:62
14. Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther 1999;6:1751-8
15. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000;105:847-51
16. Wodarz D. Gene therapy for killing p53-negative cancer cells: Use of replicating versus nonreplicating agents. Hum Gene Ther 2003;14:153-9
17. Høgset A, Engesaeter BO, Prasmickaite L, Berg K, Fodstad O, Maelandsmo GM. Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy. Cancer Gene Ther 2002;9:365-71
18. Williams MD. Integration of biomarkers including molecular targeted therapies in head and neck cancer. Head Neck Pathol 2010;4:62-9
19. Maeda N, Kawamura T, Hoshino H, Yamada N, Blackard J, Kushida S, et al. Inhibition of human T-cell leukemia virus type 1 replication by antisense env oligodeoxynucleotide. Biochem Biophys Res Commun 1998;243:109-12
20. Cozzi PJ, Malhotra S, McAuliffe P, Kooby DA, Federoff HJ, Huryk B, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001;15:1306-8
21. Yoon SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type 1selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000;14:301-11
22. Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003;7:163-73
23. Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, et al. Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 2010;103:510-6
24. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6
25. O?Shea CC, Soria C, Bagus B, McCormick F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005;8:61-74
26. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000;60:6359-66
27. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 2000;7:588-92
28. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 2003;21:4546-52
29. Liu R, Varghese S, Rabkin SD. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-Antigen transgenic mice. Cancer Res 2005;65:1532-40
30. Nemunaitis J, Cunningham C, Tong A, Post L, Netto G, Paulson AS, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther 2003;10:341-52
31. Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA, et al. Safety of interleukin-12 gene therapy against cancer: A murine biodistribution and toxicity study. Hum Gene Ther 2003;14:1037-48
32. Manchanda P, Sharma SC, Das SN. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma. Oral Dis 2006;12:455-62
33. Fukui T, Hayashi Y, Kagami H, Yamamoto N, Fukuhara H, Tohnai I, et al. Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-Associated virus vector. Oral Oncol 2001;37:211-5
34. Neves SS, Sarmento-Ribeiro AB, Simões SP, Pedroso De Lima MC. Transfection of oral cancer cells mediated by transferrin-Associated lipoplexes: Mechanisms of cell death induced by herpes simplex virus thymidine kinase/ganciclovir therapy. Biochim Biophys Acta 2006;1758:1703-12
35. Young M, Overlid N, Konopka K, Düzgünes N. Gene therapy for oral cancer: Efficient delivery of a ?suicide gene? to murine oral cancer cells in physiological milieu. J Calif Dent Assoc 2005;33:967-71
36. Rao SK, Pavicevic Z, Du Z, Kim JG, Fan M, Jiao Y, et al. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem 2010;285:32512-21
37. Kowalczyk DW, Wysocki PJ, Mackiewicz A. Cancer immunotherapy using cells modified with cytokine genes. Acta Biochim Pol 2003;50:613-24
38. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004;101 Suppl 2:14567-71
39. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1319-24
40. Ramadoss S, Li J, Ding X, Al Hezaimi K, Wang CY. Transducin ?-like protein 1 recruits nuclear factor ?B to the target gene promoter for transcriptional activation. Mol Cell Biol 2011;31:924-34
41. Fang L, Hu Q, Hua Z, Li S, Dong W. Growth inhibition of a tongue squamous cell carcinoma cell line (Tca8113) in vitro and in vivo via siRNA-mediated down-regulation of skp2. Int J Oral Maxillofac Surg 2008;37:847-52
42. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127-35
43. Ziai J, French CA, Zambrano E. NUT gene rearrangement in a poorly-differentiated carcinoma of the submandibular gland. Head Neck Pathol 2010;4:163-8
44. Schuurhuis DH, Ioan-Facsinay A, Nagelkerken B, van Schip JJ, Sedlik C, Melief CJ, et al. Antigen-Antibody immune complexes empower dendritic cells to efficiently prime specific CD8+CTL responses in vivo. J Immunol 2002;168:2240-6
45. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002;195:1653-9
46. Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, et al. MicroRNA-200c attenuates tumour growth and metastasis of presumptive head and neck squamous cell carcinoma stem cells. J Pathol 2011;223:482-95
47. Yoo GH, Moon J, Leblanc M, Lonardo F, Urba S, Kim H, et al. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: Report of the Southwest Oncology Group. Arch Otolaryngol Head Neck Surg 2009;135:869-74
48. Mizuno M, Yoshida J, Colosi P, Kurtzman G. Adeno-Associated virus vector containing the herpes simplex virus thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration. Jpn J Cancer Res 1998;89:76-80
49. Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, et al. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ ganciclovir on cancer cells. Cancer Gene Ther 2001;8:99-106
50. Kanazawa T, Mizukami H, Nishino H, Okada T, Hanazono Y, Kume A, et al. Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells. Int J Oncol 2004;25:729-35
51. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR. Novel targeted therapeutics: Inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011;4:16
52. Xu D, McCarty D, Fernandes A, Fisher M, Samulski RJ, Juliano RL. Delivery of MDR1 small interfering RNA by self-complementary recombinant adeno-Associated virus vector. Mol Ther 2005;11:523-30
53. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002;296:1000-4
54. Yang L, Ma X, Xiao L, Tang M, Weng X, Sun L, et al. Uniquely modified RNA oligonucleotides targeting STAT3 suppress melanoma growth both in vitro and in vivo. Cancer Biol Ther 2009;8:2065-72
55. Zhang C, Wang QT, Liu H, Zhang ZZ, Huang WL. Advancement and prospects of tumor gene therapy. Chin J Cancer 2011;30:182-8